Back

Is beta- blocker therapy beneficial among patients with heart failure and reduced ejection fraction with concomitant atrial fibrillation rhythm?

17 May 2025 (11:00 - 12:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - heart failure with HFrEF (2) Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Fadel Bahouth

EMMS Nazareth Hospital, Nazareth (Israel)

7 More presentations in this session

Presentation thumbnail
Association between ultra-short-term heart rate variability and atrial fibrillation in heart failure population
Doctor X. Tang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
The prognostic value of the CONUT score in predicting long-term mortality in acute decompensated heart failure patients
Associate Professor S. Murat (Eskisehir, TR)
Abstract Slides Video
Presentation thumbnail
Clinical efficacy of heart failure guideline directed medical therapy in patients with titin-truncating variants-associated dilated cardiomyopathy
Doctor A. Cerar (Ljubljana, SI)
Abstract Slides Video
Presentation thumbnail
Qiliqiangxin improves cardiovascular outcomes in patients with heart failure and reduced ejection fraction irrespective of left ventricular ejection fraction
Doctor L. Shen (Glasgow, CN)
Abstract Slides Video
Presentation thumbnail
Role of telemedicine in improving care for heart failure patients
Doctor A. Bakhsh (Makkah, SA)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - heart failure with HFrEF (2)

The Event

Event poster

Heart Failure 2025

17 May 2025 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Contemporary use of beta-blockers in the outpatient treatment of heart failure with atrial fibrillation
thumbnail
Congress Presentation
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
thumbnail
Congress Presentation
Impact of af on sacubitril/valsartan dosing, persistance of treatment and associated outcomes in heart failure patients with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources